04:00 AM EST, 03/03/2025 (MT Newswires) -- AbbVie ( ABBV ) has signed a license deal with contract research firm Gubra to develop GUB014295 for the treatment of obesity, the companies said Monday.

Under the license deal, AbbVie ( ABBV ) will lead the development and commercialization of the drug, while Gubra will receive a $350 million upfront payment, and up to $1.88 billion in potential milestone payments with tiered royalties on sales.

The deal is subject to regulatory and other closing conditions.